CorMedix Inc.(NYSEMKT:CRMD) declareda presentation on Neutrolin® post marketing surveillance data at the 52nd European Dialysis and Transplant Association (ERA-EDTA) Congress. The Neutrolin Usage Monitoring Program is a post-approval surveillance program monitoring the routine use of Neutrolin, a novel catheter lock solution, in hemodialysis patients with tunneled central venous catheters (CVC). The program measures the number of catheter associated blood stream infections (CRBSI), and the number of pre-mature CVC removals due to infection and/ or thrombosis. The secondary outcome measure was biofilm formation in CVCs. Other outcome measures comprised economic effects derived from using Neutrolin and effectiveness in the high risk groups (e.g. diabetic patients).
CorMedix Inc.(NYSEMKT:CRMD)started its trading session with the price of $ 4.91and closed at $ 5.02by scoring + 2.03% and traded with total volume of 1.15M shares, while the average trading remained 729,882.00 shares. During last trade its minimum price was $ 4.33 and it gained the highest price of $ 5.05. Its market capitalization was $ 152.78M.
22nd Century Group Inc(NYSEMKT:XXII) reported that its entirely owned subsidiary, Goodrich Tobacco Company, LLC, has been granted both a New York State Cigarette Stamping Agent license and a New York State Wholesale Cigarette Dealer license. With these licenses, the Company gains the ability to distribute its RED SUN cigarettes across New York State without the need to use a middle-man distributor.
22nd Century Group Inc(NYSEMKT:XXII) showing dropped of -5.88% and closed at $ 0.920, after gaining total volume of 1.13M shares. Its opening price was $ 1.02. Its earnings per share(EPS) is $ -0.23 and its beta value stands at 29.66 points and has total market capitalization of $ 69.27M and a total of 70.87M outstanding shares.
Lion Biotechnologies Inc(NASDAQ:LBIO) releasedthat the FDA has granted orphan status to the company’s lead product candidate, LN-144, for the treatment of stage 2b to stage 4 malignant melanoma.The FDA grants orphan status to novel drugs or biologics to treat rare medical diseases or conditions that affect fewer than 200,000 people in the United States. By receiving this designation for LN-144, Lion will be entitled for tax credits for clinical testing, exemption from a prescription drug user fee, and seven years of market exclusivity.
Lion Biotechnologies Inc(NASDAQ:LBIO) reported the surge of 5.52% and closed at $ 11.66, with the total traded volume of 1.13M shares and opening price was $11.01. During last trade its minimum price was $10.80 and it gained its highest price of $12.00 and has a total of 45.03M outstanding shares and its total market capitalization is $498.65M.
Perrigo Company plc Ordinary Shares(NYSE:PRGO) publicizedthat it has entered into an agreement to acquire a portfolio of well-established over-the-counter (“OTC”) brands from GlaxoSmithKline Consumer Healthcare (“GSK”), in connection with GSK’s commitments to the European Commission and other regulators to divest these businesses in the context of the formation of a consumer health collaboration between GSK and Novartis International AG (“Novartis”).
Perrigo Company plc Ordinary Shares(NYSE:PRGO) reported the decline of -0.69%, after closing price for the day was $ 183.30 and opening at the price of $ 183.35. Its total trading volume for the day was 1.12M shares, versus its average volume of 1.15M shares. Its earnings per share are $ 1.62.